Clinical-stage biopharma company Cybin Inc. (NYSE: CYBN) has completed participant dosing on the part 2 of 3 of its Phase 1 trial assessing intravenous (IV) administration of proprietary DMT drug CYB004.
While the trial evaluates safety and efficacy of escalating doses of DMT and CYB004 in healthy volunteers, the novel drug -a deuterated DMT molecule- is being assessed as a potential treatment for Generalized Anxiety Disorder (GAD) with or without Major Depressive Disorder (MDD.)
CEO Doug Drysdale said the third …